[{"id":"4346ba5f-67b8-4706-8e12-549591ad58c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06696768","created_at":"2025-02-25T20:15:51.863Z","updated_at":"2025-02-25T20:15:51.863Z","phase":"Phase 1","brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06696768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • IL6 • CCL2 • CXCL1 • IRAK4","pipe":"","alterations":" ","tags":["IFNG • IL6 • CCL2 • CXCL1 • IRAK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-16"},{"id":"894d41c8-fa82-4742-ae07-cc5efd0a178a","acronym":"EARDIS","url":"https://clinicaltrials.gov/study/NCT05648240","created_at":"2022-12-13T14:58:01.312Z","updated_at":"2024-07-02T16:35:20.013Z","phase":"","brief_title":"Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps","source_id_and_acronym":"NCT05648240 - EARDIS","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" CXCL12 • TIMP1 • CCL2 • CSF2 • CXCL1","pipe":"","alterations":" ","tags":["CXCL12 • TIMP1 • CCL2 • CSF2 • CXCL1"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/23/2023","start_date":" 02/23/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-09"},{"id":"fcb310b1-7109-4950-b9ce-a0716eaa4d58","acronym":"FoCus","url":"https://clinicaltrials.gov/study/NCT06191120","created_at":"2024-01-04T16:18:07.968Z","updated_at":"2024-07-02T16:35:23.000Z","phase":"","brief_title":"FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype","source_id_and_acronym":"NCT06191120 - FoCus","lead_sponsor":"UMC Utrecht","biomarkers":" CXCL8 • ACTA2 • FAP • COL1A1 • MMP1 • RSPO3 • CXCL1 • CXCL14 • MMP3 • BMP4","pipe":" | ","alterations":" FAP expression","tags":["CXCL8 • ACTA2 • FAP • COL1A1 • MMP1 • RSPO3 • CXCL1 • CXCL14 • MMP3 • BMP4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2024-01-18"},{"id":"c15a52de-3419-47f0-9b51-09f2e18386cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05964985","created_at":"2023-07-31T17:08:51.096Z","updated_at":"2024-07-02T16:35:41.679Z","phase":"","brief_title":"Effect of Quadratus Lumborum Block With Compound Lidocaine and Esketamine on Pain After Colorectal Surgery","source_id_and_acronym":"NCT05964985","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 08/06/2023","start_date":" 08/06/2023","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 02/15/2024","study_completion_date":" 02/15/2024","last_update_posted":"2023-07-28"},{"id":"271e7fdf-8d02-4873-b54f-f0cc79e784c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03406299","created_at":"2021-01-18T14:26:32.423Z","updated_at":"2024-07-02T16:35:50.949Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT03406299","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" CDKN2A • ARID1A • IL6 • HGF • CXCL1 • CXCL3","pipe":"","alterations":" ","tags":["CDKN2A • ARID1A • IL6 • HGF • CXCL1 • CXCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-04-11"},{"id":"4b7e0b24-03c6-4d32-b451-a9a4d7917763","acronym":"","url":"https://clinicaltrials.gov/study/NCT02120807","created_at":"2021-04-27T22:53:05.162Z","updated_at":"2024-07-02T16:35:56.991Z","phase":"Phase 1","brief_title":"Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas","source_id_and_acronym":"NCT02120807","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TNFA • CXCL1","pipe":"","alterations":" ","tags":["TNFA • CXCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/15/2014","start_date":" 04/15/2014","primary_txt":" Primary completion: 01/24/2023","primary_completion_date":" 01/24/2023","study_txt":" Completion: 01/24/2023","study_completion_date":" 01/24/2023","last_update_posted":"2023-01-26"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"420161af-0789-415c-a89a-f5a0d30baaa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221593","created_at":"2022-02-05T18:29:05.927Z","updated_at":"2024-07-02T16:36:02.016Z","phase":"Phase 3","brief_title":"Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients","source_id_and_acronym":"NCT05221593","lead_sponsor":"Al-Azhar University","biomarkers":" CXCL12 • CXCL1","pipe":"","alterations":" ","tags":["CXCL12 • CXCL1"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-10-21"},{"id":"110ea52b-e84e-4c4f-ac59-5c89e4d16963","acronym":"EPITHEM","url":"https://clinicaltrials.gov/study/NCT04576429","created_at":"2021-01-18T21:50:49.552Z","updated_at":"2024-07-02T16:36:16.766Z","phase":"","brief_title":"Immune Profiles Evolution Under Immunotherapy for Melanoma","source_id_and_acronym":"NCT04576429 - EPITHEM","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/01/2031","primary_completion_date":" 01/01/2031","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2022-02-23"},{"id":"5a88e172-f3f1-4d49-981a-f074496e0ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05122338","created_at":"2021-11-16T12:53:42.048Z","updated_at":"2024-07-02T16:36:20.673Z","phase":"","brief_title":"Effect of Transversus Abdominis Plane Block With Compound Lidocaine and Esketamine on Pain After Surgery","source_id_and_acronym":"NCT05122338","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 05/15/2022","primary_completion_date":" 05/15/2022","study_txt":" Completion: 06/15/2022","study_completion_date":" 06/15/2022","last_update_posted":"2021-11-16"},{"id":"712e9fbe-5df9-4835-8a1d-b353c3c1de22","acronym":"","url":"https://clinicaltrials.gov/study/NCT04732442","created_at":"2021-02-01T16:58:07.704Z","updated_at":"2024-07-02T16:36:35.333Z","phase":"","brief_title":"Changes in Inflammatory Response After Immunonutrition Compared to Standard Nutrition in Colorectal Cancer Tissue","source_id_and_acronym":"NCT04732442","lead_sponsor":"Jagiellonian University","biomarkers":" TNFA • CXCL8 • CXCL12 • CXCL2 • CXCL6 • CXCL1 • MPO","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • CXCL12 • CXCL2 • CXCL6 • CXCL1 • MPO"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 01/30/2019","study_completion_date":" 01/30/2019","last_update_posted":"2021-02-01"},{"id":"2c1a0196-3aa8-4a4d-a3bf-dff96dbec5d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00882765","created_at":"2021-01-18T03:22:38.145Z","updated_at":"2024-07-02T16:36:42.526Z","phase":"Phase 2","brief_title":"Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00882765","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" VEGFA • CXCL8 • CXCL5 • CXCL1","pipe":"","alterations":" ","tags":["VEGFA • CXCL8 • CXCL5 • CXCL1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-31"},{"id":"7fba638b-74ab-4258-8262-3145906d3995","acronym":"CHEMOPROST","url":"https://clinicaltrials.gov/study/NCT02869282","created_at":"2021-01-18T14:05:05.897Z","updated_at":"2024-07-02T16:37:29.701Z","phase":"","brief_title":"STUDY OF THE EXPRESSION OF CIRCULATING AND INTRA-TUMORAL CHEMOKINES IN PATIENTS WITH PROSTATE CANCER","source_id_and_acronym":"NCT02869282 - CHEMOPROST","lead_sponsor":"Institut Bergonié","biomarkers":" IL6 • CXCL8 • CXCL12 • CXCL5 • CXCL1","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • CXCL12 • CXCL5 • CXCL1"],"overall_status":"Unknown status","enrollment":" Enrollment 145","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2016-08-17"}]